Famitinib
Phase 3Small molecule
Famitinib is a small molecule that works as a Platelet-Derived Growth Factor Receptor Inhibitor; Stem Cell Growth Factor Receptor Inhibitor; Tyrosine-Protein Kinase Receptor FLT3 Inhibitor; Vascular Endothelial Growth Factor Receptor 1 Inhibitor; Vascular Endothelial Growth Factor Receptor 2 Inhibitor; Vascular Endothelial Growth Factor Receptor 3 Inhibitor.[2] It is being investigated across 19 indications, with its most advanced program in Phase 3.[1]
Famitinib is one of 501 small molecule programs targeting Nasopharyngeal Carcinoma. It is currently in Phase 3.
19
Indications
39
Total Trials
10
Active Trials
500
Competitors
Pipeline
Status by Indication[3][1]
Indication
Showing 10 of 19 indications
Competition
Competitive Landscape
2828 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Famitinib
JJiangsu HengRui Medicine Co., Ltd.
Phase 3
Gemzar
GGynecologic Oncology Group
Preclinical
Chirocaine
PPurdue Pharma LP
Preclinical
Tricor
JJagotec
Preclinical
Cortef
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Avastin
RochePreclinical
Paracetamol
GSKPreclinical
Systemic Therapy
Bristol-Myers SquibbPreclinical
Bisphosphonate
AmgenPreclinical
Recombinant Human Chorionic Gonadotropin
Merck & Co.Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Breast Cancer8 trials
A Study of SHR6390 Combined With Famitinib in the Treatment of HR + / HER2- Advanced Breast Cancer.
Unknown status·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT04733417·35 enrolled
Show 5 more trials
Nasopharyngeal Carcinoma3 trials
Intrahepatic Cholangiocarcinoma2 trials
Non-Small Cell Lung Cancer2 trials
22 more indications
First-line Treatment1 trial
Metastatic Renal Cell Cancer1 trial
Patients With Advanced Solid Tumors1 trial
Interaction1 trial
Gastrointestinal Stromal Tumour1 trial
Adjuvant Treatment1 trial
Osteosarcoma1 trial
Pancreatic Neuroendocrine Tumor1 trial
Cervical Cancer1 trial
Advanced NSCLC1 trial
Ovarian Cancer1 trial
Chemotherapy1 trial
Camrelizumab1 trial
Gynecological Tumors1 trial
Colorectal Adenocarcinoma1 trial
Advanced Solid Tumor1 trial
Gastrointestinal Stromal Tumor1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Famitinib. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Platelet-Derived Growth Factor Receptor Inhibitor; Stem Cell Growth Factor Receptor Inhibitor; Tyrosine-Protein Kinase Receptor FLT3 Inhibitor; Vascular Endothelial Growth Factor Receptor 1 Inhibitor; Vascular Endothelial Growth Factor Receptor 2 Inhibitor; Vascular Endothelial Growth Factor Receptor 3 Inhibitor[2]
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]